FOLD Insider Trading
AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at AMICUS THERAPEUTICS, INC. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2015-07-16 00:03 | 2015-07-13 | SBLENDORIO GLENN | Director | OPT+S | $15.00 | 10,000 | $150,000 | 11,933 | 0.0% |
| 2015-07-16 00:02 | 2015-07-13 | Crowley John F | Director, Officer - Chairman & CEO | OPT+S | $15.03 | 150,000 | $2,253,990 | 83,499 | 0.0% |
| 2015-07-10 01:26 | 2015-07-08 | Doshi Dipal | Officer - SVP Strategy & Bus Dev | OPT+S | $13.87 | 6,250 | $86,689 | 1,706 | 0.0% |
| 2015-07-02 00:28 | 2015-07-01 | Quimi Daphne | Officer - Vice President Finance | OPT+S | $13.98 | 2,600 | $36,350 | 8,188 | 0.0% |
| 2015-07-02 00:27 | 2015-07-01 | Peist Kenneth | Officer - VP, Legal & IP | OPT+S | $13.98 | 10,000 | $139,766 | 3,187 | 0.0% |
| 2015-07-02 00:27 | 2015-07-01 | Gershkowitz Jayne | Officer - SVP, Chief Patient Advocate | OPT+S | $13.97 | 10,649 | $148,818 | 5,693 | 0.0% |
| 2015-06-25 02:08 | 2015-06-22 | Valenzano Ken | Officer - SVP, Pharmacology & Biology | OPT+S | $13.85 | 20,500 | $284,013 | 27,687 | 0.0% |
| 2015-06-25 02:07 | 2015-06-22 | Castelli Jeff | Officer - SVP, Program Management | OPT+S | $13.94 | 18,981 | $264,627 | 25,000 | 0.0% |
| 2015-06-25 02:06 | 2015-06-23 | HAYDEN DONALD J JR | Director | OPT+S | $14.01 | 55,000 | $770,391 | 0 | 0.0% |
| 2015-06-24 03:09 | 2015-06-19 | Dilone Enrique | Officer - SVP, Technical Operations | OPT+S | $13.26 | 14,045 | $186,275 | 30,688 | 0.0% |
| 2015-06-24 03:08 | 2015-06-19 | Campbell Bradley L | Officer - Chief Operating Officer | OPT+S | $13.26 | 13,000 | $172,424 | 156,575 | 0.0% |
| 2015-06-24 03:08 | 2015-06-19 | Baird William D III | Officer - Chief Financial Officer | OPT+S | $13.26 | 15,235 | $202,057 | 56,575 | 0.0% |
| 2015-06-17 03:14 | 2015-06-15 | Yu Julie | Officer - VP Clinical Ops & Data Mgmt | SELL | $14.17 | 8,195 | $116,123 | 0 | -100.0% |
| 2015-06-17 03:14 | 2015-06-15 | Castelli Jeff | Officer - SVP, Program Management | SELL | $14.17 | 7,377 | $104,532 | 0 | -100.0% |
| 2015-06-08 23:53 | 2015-06-08 | Crowley John F | Director, Officer - Chairman & CEO | OPT+S | $13.01 | 55,000 | $715,550 | 83,499 | 0.0% |
| 2015-06-08 23:53 | 2015-06-08 | Castelli Jeff | Officer - SVP, Program Management | OPT+S | $12.87 | 17,312 | $222,805 | 25,000 | 0.0% |
| 2015-05-13 04:47 | 2015-05-11 | Valenzano Ken | Officer - SVP, Pharmacology & Biology | OPT+S | $10.85 | 13,000 | $141,010 | 2,687 | 0.0% |
| 2015-05-13 04:46 | 2015-05-11 | Yu Julie | Officer - VP Clinical Ops & Data Mgmt | OPT+S | $10.85 | 7,500 | $81,339 | 8,195 | 0.0% |
| 2015-05-13 04:44 | 2015-05-11 | Quimi Daphne | Officer - VP Finance and Controller | OPT+S | $10.84 | 7,500 | $81,306 | 8,188 | 0.0% |
| 2015-05-13 04:44 | 2015-05-11 | Peist Kenneth | Officer - VP, Legal & IP | OPT+S | $10.84 | 12,500 | $135,488 | 3,187 | 0.0% |
| 2015-05-13 04:43 | 2015-05-11 | Kirk John | Officer - VP, Regulatory Affairs | OPT+S | $10.84 | 10,000 | $108,358 | 5,687 | 0.0% |
| 2015-05-13 04:42 | 2015-05-11 | Gershkowitz Jayne | Officer - SVP, Chief Patient Advocate | OPT+S | $10.84 | 10,000 | $108,389 | 5,693 | 0.0% |
| 2015-05-13 04:41 | 2015-05-11 | Dilone Enrique | Officer - SVP, Technical Operations | OPT+S | $10.85 | 10,000 | $108,450 | 5,688 | 0.0% |
| 2015-05-13 04:41 | 2015-05-11 | Castelli Jeff | Officer - SVP, Program Management | OPT+S | $10.84 | 10,000 | $108,371 | 7,377 | 0.0% |
| 2015-05-13 04:40 | 2015-05-11 | Campbell Bradley L | Officer - Chief Operating Officer | OPT+S | $10.84 | 24,800 | $268,810 | 6,575 | 0.0% |
| 2015-05-13 04:40 | 2015-05-11 | Baird William D III | Officer - Chief Financial Officer | OPT+S | $10.84 | 24,800 | $268,810 | 6,575 | 0.0% |
| 2015-04-18 00:03 | 2015-04-15 | Valenzano Ken | Officer - VP, Pharmacology & Biology | OPT+S | $12.50 | 5,000 | $62,500 | 50,000 | 0.0% |
| 2015-04-18 00:02 | 2015-04-15 | SBLENDORIO GLENN | Director | OPT+S | $12.50 | 20,000 | $250,000 | 11,933 | 0.0% |
| 2015-04-13 23:09 | 2015-04-10 | Crowley John F | Director, Officer - Chairman & CEO | OPT+S | $12.00 | 11,678 | $140,136 | 83,499 | 0.0% |
| 2015-04-03 03:35 | 2015-04-01 | Castelli Jeff | Officer - VP, Program Management | OPT+S | $10.69 | 9,489 | $101,480 | 50,000 | 0.0% |
| 2015-03-25 13:23 | 2015-03-20 | Valenzano Ken | Officer - VP, Pharmacology & Biology | OPT+S | $11.77 | 7,751 | $91,239 | 50,000 | 0.0% |
| 2015-03-25 13:22 | 2015-03-20 | Yu Julie | Officer - VP Clinical Ops & Data Mgmt | OPT+S | $11.51 | 7,785 | $89,585 | 50,000 | 0.0% |
| 2015-03-25 04:53 | 2015-03-20 | Valenzano Ken | Officer - VP, Pharmacology & Biology | OPT+S | $11.53 | 13,050 | $150,500 | 50,000 | 0.0% |
| 2015-03-25 04:52 | 2015-03-20 | Peist Kenneth | Officer - VP, Legal & IP | OPT+S | $11.52 | 10,000 | $115,160 | 50,000 | 0.0% |
| 2015-03-25 04:51 | 2015-03-20 | Kirk John | Officer - VP, Regulatory Affairs | OPT+S | $11.51 | 10,110 | $116,359 | 50,000 | 0.0% |
| 2015-03-25 04:51 | 2015-03-20 | Gershkowitz Jayne | Officer - VP, Patient Advocacy | OPT+S | $11.51 | 10,648 | $122,568 | 50,000 | 0.0% |
| 2015-03-25 04:50 | 2015-03-20 | Dilone Enrique | Officer - VP, Technical Operations | OPT+S | $11.51 | 14,045 | $161,669 | 50,000 | 0.0% |
| 2015-03-25 04:50 | 2015-03-20 | Crowley John F | Director, Officer - Chairman & CEO | OPT+S | $11.49 | 268,322 | $3,082,242 | 83,499 | 0.0% |
| 2015-03-25 04:49 | 2015-03-20 | Campbell Bradley L | Officer - Chief Operating Officer | OPT+S | $11.51 | 12,999 | $149,595 | 200,000 | 0.0% |
| 2015-03-25 04:48 | 2015-03-20 | Baird William D III | Officer - Chief Financial Officer | OPT+S | $11.51 | 15,235 | $175,294 | 100,000 | 0.0% |
| 2015-01-06 01:32 | 2015-01-05 | Castelli Jeff | Officer - VP, Program Management | OPT+S | $9.00 | 4,667 | $42,003 | 50,000 | 0.0% |
| 2014-12-09 02:14 | 2014-12-04 | Crowley John F | Director, Officer - Chairman & CEO | OPT+S | $8.36 | 89,000 | $743,907 | 109,083 | 0.0% |
| 2014-12-09 02:14 | 2014-12-04 | Crowley John F | Director, Officer - Chairman & CEO | BUY | $8.36 | 89,000 | $743,907 | 198,083 | +81.6% |
| 2014-11-26 01:37 | 2014-11-25 | Valenzano Ken | Officer - VP, Pharmacology & Biology | OPT+S | $8.00 | 25,000 | $200,000 | 50,000 | 0.0% |
| 2014-11-26 01:37 | 2014-11-25 | Valenzano Ken | Officer - VP, Pharmacology & Biology | BUY | $8.00 | 25,000 | $200,000 | 75,000 | +50.0% |
| 2014-11-26 01:36 | 2014-11-25 | Quimi Daphne | Officer - VP Finance and Controller | OPT+S | $8.00 | 3,500 | $28,000 | 50,000 | 0.0% |
| 2014-11-26 01:36 | 2014-11-25 | Quimi Daphne | Officer - VP Finance and Controller | BUY | $8.00 | 3,500 | $28,000 | 53,500 | +7.0% |
| 2014-11-26 01:36 | 2014-11-25 | Peist Kenneth | Officer - VP, Legal & IP | OPT+S | $8.00 | 4,500 | $36,000 | 50,000 | 0.0% |
| 2014-11-26 01:36 | 2014-11-25 | Peist Kenneth | Officer - VP, Legal & IP | BUY | $8.00 | 4,500 | $36,000 | 54,500 | +9.0% |
| 2014-11-26 01:35 | 2014-11-25 | Dilone Enrique | Officer - VP, Technical Operations | OPT+S | $8.00 | 7,000 | $56,000 | 50,000 | 0.0% |
How to Interpret $FOLD Trades
Not every insider transaction in AMICUS THERAPEUTICS, INC. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $FOLD shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for FOLD
Insider activity data for AMICUS THERAPEUTICS, INC. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $FOLD, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.